I thought it was generally agreed that the "nukes" would be the backbone of an all-oral HCV treatment. So why is BMY spending money testing its NS5A inhibitor with JNJ's TMC435? Could it be possible to have a three-drug combo, each from a different company? (BMY's NS5A inhibitor, JNJ's PI from Medivir and GILD's nuke from VRUS)
Market Data 
Markets 
AI
